Literature DB >> 17976353

A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction.

Barbara P Yawn1, Patricia Saddier, Peter C Wollan, Jennifer L St Sauver, Marge J Kurland, Lina S Sy.   

Abstract

OBJECTIVE: To establish accurate, up-to-date, baseline epidemiological data for herpes zoster (HZ) before the introduction of the recently licensed HZ vaccine.
METHODS: Using data from January 1, 1996, to October 15, 2005, we conducted a population-based study of adult residents (Greater than or equal to 22 years) of Olmsted County, MN, to determine (by medical record review) the incidence of HZ and the rate of HZ-related complications. Incidence rates were determined by age and sex and adjusted to the US population.
RESULTS: A total of 1669 adult residents with a confirmed diagnosis of HZ were identified between January 1, 1996, and December 31, 2001. Most (92%) of these patients were immunocompetent and 60% were women. When adjusted to the US adult population, the incidence of HZ was 3.6 per 1000 person-years (95% confidence interval, 3.4-3.7), with a temporal increase from 3.2 to 4.1 per 1000 person-years from 1996 to 2001. The incidence of HZ and the rate of HZ-associated complications increased with age, with 68% of cases occurring in those aged 50 years and older. Postherpetic neuralgia occurred in 18% of adult patients with HZ and in 33% of those aged 79 years and older. Overall, 10% of all patients with HZ experienced 1 or more nonpain complications.
CONCLUSIONS: Our population-based data suggest that HZ primarily affects immunocompetent adults older than 50 years; 1 in 4 experiences some type of HZ-related complication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17976353     DOI: 10.4065/82.11.1341

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  252 in total

1.  The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study.

Authors:  Mélanie Drolet; Marc Brisson; Kenneth E Schmader; Myron J Levin; Robert Johnson; Michael N Oxman; David Patrick; Caty Blanchette; James A Mansi
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

2.  A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011.

Authors: 
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

3.  Post-shingles neuralgia by any definition is painful, but is it PHN?

Authors:  Barbara P Yawn
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

Review 4.  Epidemiology of neuropathic pain and its impact on quality of life.

Authors:  Blair H Smith; Nicola Torrance
Journal:  Curr Pain Headache Rep       Date:  2012-06

5.  A 69-year-old man with a painful vesicular rash.

Authors:  Derek R MacFadden; Wayne L Gold
Journal:  CMAJ       Date:  2012-07-09       Impact factor: 8.262

6.  Zoster vaccination: A new opportunity for adult immunization.

Authors:  Kevin B Laupland; David N Fisman
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

7.  Herpes zoster increased risk of neuralgic amyotrophy: a retrospective, population-based matched cohort study.

Authors:  Tsung-Yen Ho; Chi-Hsiang Chung; Yu-Ping Shen; Liang-Cheng Chen; Wu-Chien Chien; Yung-Tsan Wu
Journal:  J Neurovirol       Date:  2018-11-05       Impact factor: 2.643

Review 8.  The global epidemiology of herpes zoster.

Authors:  Barbara P Yawn; Don Gilden
Journal:  Neurology       Date:  2013-09-03       Impact factor: 9.910

9.  Chronic medical conditions as risk factors for herpes zoster.

Authors:  Riduan M Joesoef; Rafael Harpaz; Jessica Leung; Stephanie R Bialek
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

10.  Herpes zoster and postherpetic neuralgia in Catalonia (Spain).

Authors:  Luis Salleras; Montse Salleras; Patricia Salvador; Núria Soldevila; Andreu Prat; Patricio Garrido; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.